Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin–tazobactam/amoxicillin–clavulanate | Zendy

Benjamin A. Lipsky | Zendy; Philip Giordano | Zendy; Shurjeel Choudhri | Zendy; James Song | Zendy

Open Access

Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin–tazobactam/amoxicillin–clavulanate

Author(s) -

Benjamin A. Lipsky,

Philip Giordano,

Shurjeel Choudhri,

James Song

Publication year - 2007

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkm130

Subject(s) - piperacillin/tazobactam , medicine , piperacillin , amoxicillin , moxifloxacin , tazobactam , clavulanic acid , beta lactamase inhibitors , antibacterial agent , ertapenem , antibiotics , anesthesia , meropenem , microbiology and biotechnology , biology , antibiotic resistance , bacteria , genetics , pseudomonas aeruginosa

Complicated skin and skin structure infections (cSSSIs), including diabetic foot infections (DFIs), are often polymicrobial, requiring combination or broad-spectrum therapy. Moxifloxacin, a broad-spectrum fluoroquinolone, is approved for cSSSI and can be administered by either intravenous (iv) or oral routes. To assess the efficacy of moxifloxacin for treating DFIs, we analysed a subset of patients with these infections who were enrolled in a prospective, double-blind study that compared the efficacy of moxifloxacin with piperacillin-tazobactam and amoxicillin-clavulanate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research